23andMe Holding Co. - Common Stock (ME)

23andMe files for Chapter 11 bankruptcy, raising concerns about genetic data security as legal challenges emerge over a $30 million data breach settlement.

U.S. stock futures declined on Tuesday, after advancing for two consecutive sessions on Friday and Monday.

The S&P 500 and Nasdaq posted their best gains in months, with the S&P 500 climbing 1.76% to 5,767.57 and the Nasdaq rising 2.3% to 18,188.59.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Shares of 23andMe are falling in premarket trading after the company filed for Chapter 11 bankruptcy to initiate a court-supervised sale process aimed at maximizing business value.

Stock futures rise on bullish sentiment as Trump administration plans targeted tariffs against trading partners.

Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities

Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki’s proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchange Commission earlier today, represented an 84% decrease to the $2.53 per share price included in the joint non-binding proposal previously submitted by Ms. Wojcicki and her then co-bidder on February 20, 2025.

Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.

Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants

SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the Company’s assets, licensing of assets, restructuring, or other strategic action.

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges

Here's the latest M&A news and auction block updates. Among the most watched items: a TikTok deal is still in flux.

23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care